Effects of prasugrel on platelet inhibition during systemic endotoxaemia: a randomized controlled trial.
P2Y(12) receptor antagonists have become a mainstay for the treatment of CVD (cardiovascular diseases). However, they have rarely been evaluated under pathophysiological conditions apart from arterial diseases. We hypothesized interactions between prasugrel and enhanced vWF (von Willebrand Factor) release in a model of systemic inflammation, and compared the pharmacodynamic effects of prasugrel against placebo on agonist-induced platelet aggregation and shear-induced platelet plug formation. A total of 20 healthy male volunteers were enrolled in a double-blind placebo-controlled two-way crossover trial. Each volunteer received either placebo or a 60 mg loading dose of prasugrel 2 h before endotoxin or placebo infusion. Platelet inhibition was measured with MEA (multiple electrode aggregometry), the PFA-100 system and the VASP (vasodilator-stimulated phosphoprotein) phosphorylation assay. Prasugrel blunted various platelet aggregation pathways, including those induced by ADP (-81%), AA (arachidonic acid) (-60%), ristocetin (-75%; P<0.001 for all) and, to a lesser degree, collagen or TRAP (thrombin-receptor-activating peptide). Prasugrel decreased shear-induced platelet plug formation, but vWF release during endotoxaemia partly antagonized the inhibitory effect of prasugrel as measured with the PFA-100 system. Endotoxaemia acutely decreased ristocetin and TRAP-induced platelet aggregation, and enhanced ristocetin-induced aggregation after 24 h. Strong in vivo blockade of P2Y(12) inhibits a broad spectrum of platelet aggregation pathways. However, vWF release may reduce prasugrel's effects under high-shear conditions.
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Alexander O
AO
Spiel
Ulla
U
Derhaschnig
Michael
M
Schwameis
Johann
J
Bartko
Jolanta M
JM
Siller-Matula
Bernd
B
Jilma
D000328:Adult; D015415:Biomarkers / Q000097:blood; D015815:Cell Adhesion Molecules / Q000097:blood; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D019446:Endotoxemia / Q000097:blood / Q000139:chemically induced / Q000503:physiopathology*; D004926:Escherichia coli; D005434:Flow Cytometry; D006801:Humans; D008070:Lipopolysaccharides / Q000008:administration & dosage; D008297:Male; D008840:Microfilament Proteins / Q000097:blood; D010750:Phosphoproteins / Q000097:blood; D010879:Piperazines / Q000008:administration & dosage / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects*; D000068799:Prasugrel Hydrochloride; D058921:Purinergic P2Y Receptor Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D013876:Thiophenes / Q000008:administration & dosage / Q000494:pharmacology*; D014841:von Willebrand Factor / Q000378:metabolism*; D000098662:Vasodilator-Stimulated Phosphoprotein
D015415:Biomarkers; D015815:Cell Adhesion Molecules; D008070:Lipopolysaccharides; D008840:Microfilament Proteins; D010750:Phosphoproteins; D010879:Piperazines; D058921:Purinergic P2Y Receptor Antagonists; D013876:Thiophenes; D000098662:Vasodilator-Stimulated Phosphoprotein; D014841:von Willebrand Factor; D000068799:Prasugrel Hydrochloride